Pascal Soriot (AP Images)
July 27, 2020 06:14 AM EDTUpdated July 28, 05:02 AM
Deals

As­traZeneca mines an­oth­er $6B ADC from Dai­ichi Sankyo, with block­buster am­bi­tions to ‘re­de­fine treat­ment stan­dards’

Amber Tong

Pas­cal So­ri­ot isn’t let­ting the all-con­sum­ing R&D and man­u­fac­tur­ing work on a Covid-19 vac­cine slow down his hunt for As­traZeneca’s next block­buster can­cer drugs. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times